GFM
SLN

GF Fund Management’s Silence Therapeutics SLN Stock Holding History

GF Fund Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.52K Buy
1,047
+125
+14% +$688 ﹤0.01% 602
2025
Q4 		$5.61K Sell
922
-56
-6% -$359 ﹤0.01% 619
2025
Q3 		$5.08K Sell
978
-187
-16% -$1.04K ﹤0.01% 609
2025
Q2 		$6.76K Hold
1,165
– – ﹤0.01% 606
2025
Q1 		$3.29K Buy
1,165
+178
+18% +$869 ﹤0.01% 638
2024
Q4 		$6.79K Buy
+987
New +$12.7K ﹤0.01% 592

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

GF Fund Management's SLN Position: Q1 2026 in Review

GF Fund Management increased its Silence Therapeutics (SLN) stake by 14% in Q1 2026, buying an estimated $688 and bringing the position to 1,047 shares worth $5.52K. The position accounts for ﹤0.01% of the portfolio, ranked #602.

GF Fund Management first reported a position in SLN in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.79K in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • GF Fund Management held 1,047 shares of Silence Therapeutics worth $5.52K as of Q1 2026.
  • GF Fund Management bought 125 Silence Therapeutics shares in Q1 2026, an estimated $688.
  • Silence Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #602 holding.
  • GF Fund Management first reported a position in Silence Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Silence Therapeutics position peaked at $6.79K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.